Because Expertise Matters
Join Cyberounds®, an online education community for health professionals Sign Up

Log In

CME

Does Timely Referral to a Nephrologist Alter ESRD Outcome?

This month, Mariya Stratilatova, M.D., and Eli A. Friedman, M.D. discuss
CME credit is no longer available for this conference.

Course Authors

Mariya Stratilatova, M.D., and Eli A. Friedman, M.D.

Dr. Stratilatova is a Fellow, Renal Disease Division, SUNY Health Sciences, Brooklyn, New York.

Dr. Stratilatova reports no conflict of interest. Within the past three years, Dr. Friedman has received grant/research support from Alteon.

Estimated course time: 1 hour(s).

Albert Einstein College of Medicine – Montefiore Medical Center designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

In support of improving patient care, this activity has been planned and implemented by Albert Einstein College of Medicine-Montefiore Medical Center and InterMDnet. Albert Einstein College of Medicine – Montefiore Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 
Learning Objectives

Upon completion of this Cyberounds®, you should be able to:

  • Assess proposed indications for nephrology consultation in progressive renal insufficiency

  • List advantages of so called "early referral" to a nephrologist

  • Discuss the limitations of studies that claimed advantage for early referral to a nephrologist

  • Evaluate the evidence that links timing of referral to a nephrologist with the subsequent probability of receiving a kidney transplant.

 

TERMS AND CONDITIONS

This conference may include discussion of commercial products and services.

The opinions expressed herein are those of the authors and do not necessarily represent the views of the sponsor or its publisher. Please review complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.

 

Please click below to accept the terms of this CME activity

Courses You Might Like

Heat Stress, Climate Change, and Its Impact on Kidney Disease

The kidneys have a major role in maintaining a healthy extracellular environment within our bodies. They also try to protect us from alterations in temperature, humidity and when access to water or food is limited. to water or food is limited.
Authors: Fumihiko Sasai, M.D., Ashio Yoshimura, M.D. and Richard J Johnson, M.D.
Estimated Time: 1 Hour
More

Home Dialysis -- The Future Is Now

Patients may benefit both in terms of quality of life and improved dialysis metrics by performing home hemodialysis.
Authors: Annie-Claire Nadeau-Fredette, M.D., and Joanne M. Bargman, M.D.; Eduardo Alas, M.D., and Mark Unruh, M.D., M.S.
Estimated Time: 1 Hour
More

Diagnosis and Treatment of Kidney Cancer

Kidney cancer, unlike other genitourinary cancers, is increasing in incidence and this is not simply due to better diagnosis.
Authors: Robert H. Weiss, M.D. and Hiromi Inoue, D.V.M.
Estimated Time: 1 Hour
More

Nephrogenic Systemic Fibrosis

This month, Frieda Wolf, M.D., discusses

idiopathic disorder in patients with renal failure who develop fibrosis in skin and internal organs after exposure to gadolinium−containing contrast agents. NSF was first noted in 1997, and published in 2000 by Cowper in the Lancet. Fifteen cases of NSF were seen in 14 dialysis patients and one patient with
Authors: Frieda Wolf, M.D.
Estimated Time: 1 Hour
More

Nephrotic Syndrome

The prognosis and therapy for nephrotic syndrome types differ.
Authors: Frieda Wolf, M.D.
Estimated Time: 1 Hour
More

Renal Transplantation: Immunity and Viral Infections

This month, Frieda Wolf, M.D., discusses

cascade of T cell activation. MHC class II proteins activate T helper cells by binding CD4 proteins on their surface. These helper cells further activate proliferation of subtypes of T cells some of which are other T helper cells, but others are cytotoxic T cells or memory T cells.
Authors: Frieda Wolf, M.D.
Estimated Time: 1 Hour
More